Targets › PABPN1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Nov 2030.
Involved in the 3'-end formation of mRNA precursors (pre-mRNA) by the addition of a poly(A) tail of 200-250 nt to the upstream cleavage product (By similarity). Stimulates poly(A) polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation reaction and also controls the poly(A) tail length (By similarity). (UniProt, Q86U42)
Open in Phaseline: the race on PABPN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Benitec Biopharma | BB-301 AAV9-delivered gene therapy encoding codon-optimized wildtype PABPN1 protein and 2 shRNAs | PABPN1 | Phase 1 | Oculopharyngeal Muscular Dystrophy | Nov 2030 |
Oculopharyngeal Muscular Dystrophy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.